Release Date: 28/06/10 09:18 Summary: Outcome of Strategic Review Price Sensitive: Yes Download Document 36.62KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%